公开(公告)号：US11458138B2

公开(公告)日：2022-10-04

申请号：US15963816

申请日：2018-04-26

Applicant: Novartis AG

Inventor： Dirk Behnke ,  Frada Berenshteyn ,  Xueshi Hao ,  Timothy Hoffman ,  Qihui Jin ,  Arnaud Lacoste ,  Cameron Lee ,  Jun Liu ,  Yahu Liu ,  Juergen Klaus Maibaum ,  Tingting Mo ,  Jianfeng Pan ,  Xin Qu ,  Jan Tchorz ,  Yun Feng Xie ,  Shanshan Yan ,  Yefen Zou

IPC: A61K31/4375 ,  A61K31/519 ,  C07D487/04 ,  C12N5/079 ,  C07D519/00 ,  A61P17/02 ,  A61K9/00 ,  A61K31/47 ,  A61K31/506 ,  A61K35/30 ,  C12N15/52 ,  C12N15/864

Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.

公开(公告)号：US09650377B2

公开(公告)日：2017-05-16

申请号：US15042924

申请日：2016-02-12

Applicant: Novartis AG

Inventor： Dirk Behnke ,  David Carcache ,  Peter Ertl ,  Manuel Koller ,  David Orain

IPC: A61K31/551 ,  C07D471/04 ,  C07D471/14 ,  A61K45/06 ,  C07D498/04

CPC classification number: C07D471/04 ,  A61K31/551 ,  A61K45/06 ,  C07D471/14 ,  C07D498/04 ,  C07D519/00

Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.